Among 141 patients (61.96 ± 10.15 years, 83 men), bMF-ICCs (33/141, 23.4%) showed significantly more CEA ≥ 5 μg/L (42.4% vs 20.2%, p = 0.01), microvascular invasion (54.5% vs 10.2%, p < 0.001), lymph node metastasis (48.5% vs 5.6%, p < 0.001), bile duct invasion (48.5% vs 5.6%, p < 0.001), and high Ki-67 expression (63.6% vs 38.9%, p = 0.01) than pMF-ICCs. The gene discussed is CEACAM5; the disease is metastatic malignant neoplasm in the lymph nodes.